UBE2C: The Potential Drug Target and Biomarker (G11065)

Target Name: UBE2C

NCBI ID: G11065

UBE2C

UBE2C: The Potential Drug Target and Biomarker

Unconventional Background

The UBE2C gene, located on chromosome 1p36.1, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The gene encodes for the UBE2C protein, which is a transmembrane protein that plays a critical role in the development and progression of these diseases.

Several studies have suggested that UBE2C may be a useful drug target for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. For instance, UBE2C has been shown to be highly expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, the UBE2C gene has been implicated in several neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Furthermore, UBE2C has also been linked to various autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and type 1 diabetes. The protein has been shown to play a crucial role in the regulation of immune responses and has been implicated in the development of autoimmune diseases.

Drug Intervention Strategies

Despite the potential benefits of UBE2C as a drug target and biomarker, the current treatment options for various diseases associated with UBE2C are limited. The UBE2C gene has not yet been approved for any clinical trials, and there are no known drugs that specifically target UBE2C.

However, researchers are exploring various strategies to intervene in UBE2C-related diseases. One approach is to develop small molecules that can inhibit the activity of UBE2C, potentially leading to the reversal of its functions. Researchers have synthesized several small molecules that target the UBE2C protein and have shown some promise in preclinical studies.

Another approach is to use UBE2C as a biomarker to diagnose and monitor diseases associated with UBE2C. Researchers have developed various methods to assess the expression of UBE2C in various tissues and have shown that UBE2C is a reliable biomarker for several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

Biomarker Potential

UBE2C has the potential to serve as a biomarker for several diseases associated with its expression. The protein has been shown to be highly expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, UBE2C has been linked to several neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Furthermore, UBE2C has also been implicated in various autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and type 1 diabetes. The protein has been shown to play a crucial role in the regulation of immune responses and has been implicated in the development of autoimmune diseases.

While UBE2C has the potential to serve as a biomarker for several diseases, its clinical utility is still being explored. Further research is needed to determine the best approach for using UBE2C as a biomarker and potential drug target.

Conclusion

In conclusion, UBE2C is a gene that has the potential to serve as a drug target and biomarker for several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. While further research is needed to determine the best approach for using UBE2C as a biomarker and potential drug target, its potential impact on the treatment options for these diseases is significant.

Protein Name: Ubiquitin Conjugating Enzyme E2 C

Functions: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-11'- and 'Lys-48'-linked polyubiquitination. Acts as an essential factor of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated ubiquitin ligase that controls progression through mitosis. Acts by initiating 'Lys-11'-linked polyubiquitin chains on APC/C substrates, leading to the degradation of APC/C substrates by the proteasome and promoting mitotic exit

The "UBE2C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets